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Background: Merkel cell polyomavirus (MCPyV) is a DNA virus expressing transcripts similar to the large T (LT) and
small T (ST) transcripts of SV40, which has been implicated in the pathogenesis of Merkel cell carcinoma (MCC), a
rare and highly aggressive neuroendocrine skin cancer. MCPyV LT antigen expression was found to be a
requirement for MCC tumor maintenance and ST protein also likely contributes to the carcinogenesis of MCC.
Previously, we have identified the probable immunodominant epitope of MCPyV LT and developed a DNA vaccine
encoding this epitope linked to calreticulin. The LT-targeting DNA vaccine generated prolonged survival, decreased
tumor size and increased LT-specific CD8+ T cells in tumor-bearing mice.
Results: In this study, we developed a MCPyV ST-expressing tumor cell line from B16 mouse melanoma cells. We
then utilized this ST-expressing tumor cell line to test the efficacy of a DNA vaccine encoding ST. In ST-expressing
tumor-bearing mice, this vaccine, pcDNA3-MCC/ST, generated a significant number of ST antigenic peptide-specific
CD8+ T cells and experienced markedly enhanced survival compared to mice vaccinated with empty vector.
Conclusions: The formation of an effective vaccine against MCPyV has the potential to advance the field of MCC
therapy and may contribute to the control of this severe malignancy through immunotherapy. Both of the
innovative technologies presented here provide opportunities to develop and test MCPyV-targeted therapies for
the control of Merkel cell carcinoma.
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Primarily occurring among elderly and immunosuppressed
individuals, Merkel cell carcinoma is a rare, although highly
aggressive neuroendocrine skin cancer. Typically sug-
gestive of a viral etiology, this pattern of occurrence led
to the discovery of Merkel cell polyomavirus (MCPyV).
MCPyV, a DNA virus expressing transcripts similar to
the large T (LT) and small T (ST) transcripts of SV40,
has been implicated in the pathogenesis of Merkel cell
carcinoma [1]. The pivotal study by Feng et al detected
MCPyV in 80% of MCC tumors compared to 16% of
control skin tissues [1] and other research groups have
corroborated this finding [2,3].* Correspondence: chung2@jhmi.edu
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reproduction in any medium, provided the orMCPyV DNA was found to be integrated into the
tumor genome of MCCs in a monoclonal pattern indi-
cating that MCPyV is the etiologic factor in the majority
of MCCs as viral integration likely occurs prior to clonal
expansion [1]. The further investigation of MCPyV T
antigen sequences in MCCs led to key insights into the
potential mechanisms of viral-mediated oncogenesis.
Remarkably, the manner in which MCPyV DNA inte-
grates in the host genome renders the virus incapable
of replicating. Additionally, although the integrated LT
protein is prematurely truncated, it retains the ability to
bind the tumor suppressor protein, retinoblastoma (Rb) [4].
These characteristic MCC tumor-specific mutations of
MCPyV are indicative of a causal role for MCPyV in
the pathogenesis of MCC.
Providing additional evidence of MCPyV as the infec-
tious cause of MCC, MCPyV LT antigen expression was
found to be required for MCC tumor maintenance [5].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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makes LT antigen an ideal immunotherapeutic target for
the treatment of MCC. In addition to LT, the MCPyV
ST protein is also likely to contribute to the carcinogen-
esis of MCC. ST shares the same amino terminus as LT,
but has a distinct carboxy terminus containing a protein
phosphatase 2A binding site, which has been shown to
be important in other polyomaviruses for virus-induced
transformation [6]. ST is expressed in most MCC tu-
mors and is required for tumor cell growth [7]. ST acts
as an oncoprotein by targeting the 4E-BP1, a transla-
tional regulator whose inhibition is required for MCPyV
transformation.
In previous studies, we identified the probable
immunodominant epitope of MCPyV LT as the span of
amino acids 19-27 [8]. Furthermore, we demonstrated
that tumor-challenged mice injected with a DNA vac-
cine encoding the 19-27 peptide linked to calreticulin
(CRT) experienced prolonged survival and decreased
tumor size [8]. The DNA vaccine also generated the
highest number of LT-specific CD8+ T cells in mice. In
the present study, we intended to utilize a DNA vaccine
encoding the ST antigen to generate an antitumor effect
in a murine tumor model expressing ST. Similar to our
previous study targeting LT, we found that vaccination
with ST DNA resulted in prolonged survival in in vivo
protection and treatment experiments in ST-expressing
tumor-challenged mice. Our data have significant im-
plications for future clinical translation.
Results
Creation of a murine tumor model that expresses MCPyV
ST antigen, B16MCC/ST
B16 mouse melanoma cells were transduced with a
lentiviral vector containing a mammalian gene encoding
MCPyV ST antigen under the control of cytomegalovirus
(CMV) promoter and GFP reporter under EF1 promoter
to generate a tumorigenic ST-expressing cell line, B16/ST.
Successful transduction of the lentivirus was confirmed by
high levels of GFP expression, which allowed us to isolate
the transduced tumor cells. As shown in Figure 1A, the
ST lentivirus-transduced B16 tumor cells demonstrated
significantly higher GFP expression levels compared to
non-transduced B16 tumor cells. The GFP-positive cells
were further isolated for the characterization of the ex-
pression of ST antigen. In order to generate antibodies
against ST antigen, mice were vaccinated with pcDNA3-
MCC/ST intramuscularly by electroporation according
to the schedule shown in Figure 1B. One month follow-
ing the last vaccination, sera from vaccinated mice were
collected for Western blot and RNA analysis. As shown
in Figure 1C and D, cell lysates from B16/ST cells dem-
onstrated a specific band consistent with ST antigen
protein and RNA levels. In comparison, cell lysates fromB16 melanoma cells did not show such a band, indicating
the absence of ST antigen. To ensure equal loading of cell
lysates, β-actin was used as a control. Thus, our data show
the successful creation of a murine B16 tumor cell line
that expresses ST, B16/ST.
Vaccination with MCPyV ST DNA generated an ST-specific
CD8+ T cell immune response
For the characterization of the ST-specific CD8+ T cell
immune response, DNA-coated particles were delivered
to the shaved abdominal region of each mouse by a
helium-driven gene gun. The vaccination schedule is
outlined in Figure 2A. The DNA vaccine we generated
encoded MCPyV ST aa 1-186 (pcDNA3-MCC/ST). Empty
pcDNA3 vector was used as a control. To determine
whether vaccination of pcDNA3-MCC/ST or pcDNA3
vaccine was capable of generating ST-specific CD8+ T
cell immune responses, intracellular cytokine staining
for IFN-γ was performed, followed by flow cytometry.
As shown in Figure 2B and C, mice vaccinated with
pcDNA3-MCC/ST generated a significant ST-specific
CD8+ T cell response when stimulated with the peptide
spanning aa 19-27. In comparison, mice vaccinated with
the empty vector pcDNA3 did not generate significant
numbers of ST-specific CD8+ T cell-mediated responses
when stimulated with the same peptides. Thus, our data
show that mice vaccinated with MCPyV ST DNA could
be generate potent ST-specific CD8+ T cell-mediated
immune responses.
Vaccination with pcDNA3-MCC/ST DNA vaccine provides
protection against challenge with ST-expressing tumor
cell line, B16/ST
Using the vaccination regimen depicted in Figure 3A, we
performed in vivo tumor protection experiments to
analyze the protective antitumor effects of pcDNA3-
MCC/ST DNA vaccine. C57BL/6 mice were vaccinated
with pcDNA3-MCC/ST DNA or pcDNA3 empty vector as
a control. Vaccinated mice were challenged with B16/
ST tumor cells subcutaneously one week after the last
vaccination. As shown in Figure 3B, mice vaccinated
with pcDNA3-MCC/ST had significantly longer sur-
vival compared to mice vaccinated with pcDNA3. Fur-
thermore, the tumor volume of mice vaccinated with
pcDNA3-MCC/ST was significantly lower than that of
mice vaccinated with pcDNA3 (Figure 3C). Thus, our
data show that pcDNA3-MCC/ST DNA vaccine generated
strong protective antitumor effects in vaccinated mice
(pcDNA3-MCC/ST vs. pcDNA3 p=0.002).
Vaccination with pcDNA3-MCC/ST DNA generates potent
therapeutic antitumor effects against ST-expressing tumors
To further determine if the treatment with pcDNA3-
MCC/ST DNA vaccine was capable of generating
Figure 1 Generation and characterization of ST-expressing B16/ST tumor cell line. B16 mouse melanoma cells were transduced with a
lentiviral vector containing a mammalian codon-optimized gene encoding Merkel cell polyomavirus (strain 350) small T antigen (ST) under the
control of cytomegalovirus and GFP reporter under EF1 promoter to generate tumorigenic B16/ST tumor cell line. (A) Characterization of the
transduction of B16/ST tumor cells by flow cytometry analysis after sorting. B16/ST tumor cells (green) or control B16 melanoma cells (purple)
were sorted and characterized for GFP expression by flow cytometry analysis. (B) Schematic diagram of vaccination schedule for Western Blot
analysis. C57BL/6 mice were vaccinated intramuscularly by electroporation three times at 1-week intervals and boosted at the same dose.
Western Blot analysis using sera from vaccinated mice was performed 1 month after last vaccination to determine ST protein levels of B16/ST
cells. (C) ST protein levels determined by Western blot analysis. Membranes were probed with either serum from mice vaccinated with
pcDNA3-MCC/ST or anti-β-actin antibody for loading control. Lane 1, negative control B16. Lane 2, B16-MCC/ST. (D) ST RNA levels determined by
RT-PCR. Lane 1, negative control B16. Lane 2, B16-MCC/ST.
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first with B16/ST tumor cells and subsequently vaccinated
the mice with pcDNA3-MCC/ST or pcDNA3 according
to the regimen outlined in Figure 4A. As shown in Figure 4B
and C, B16/ST tumor-bearing mice vaccinated with
pcDNA3-MCC/ST showed significantly longer survival
and lower tumor volume when compared to mice treated
with pcDNA3. Therefore, our data indicates that pcDNA3-
MCC/ST DNA vaccine can potentially generate thera-
peutic antitumor effects in B16/ST tumor-bearing mice
(pcDNA3-MCC/ST vs. pcDNA3 p=0.002).
The antitumor effect elicited by pcDNA3-MCC/ST DNA is
mediated by CD8+ T cells
In order to examine the impact of CD8+ T cells on the
therapeutic antitumor effect elicited by pcDNA3-MCC/ST
DNA vaccine against B16/ST tumors, we performed an
in vivo antibody depletion assay. C57BL/6 mice were
vaccinated with pcDNA3-MCC/ST three times at one week
intervals. Beginning on day 15 after the first vaccination,
mice were treated with anti-CD8 antibody every other day
and then were challenged subcutaneously with B16/STtumor cells. As shown in Figure 5A, virtually all of the
mice depleted of CD8+ T cells developed tumors, com-
pared to only 60% of non-depleted mice. Furthermore,
mice treated with anti-CD8 antibody developed signifi-
cantly larger tumors compared to mice untreated mice.
These data suggest that CD8+ T cells are essential for
the observed therapeutic antitumor effect against ST-
expressing tumors generated by the pcDNA3-MCC/ST
DNA vaccine.
Discussion
In the current study, we successfully created a murine
tumor cell line expressing MCPyV small T antigen from
the B16 cell line using a CMV promoter, which was con-
firmed by Western blot. We utilized this ST-expressing
tumor cell line to test the efficacy of a DNA vaccine en-
coding ST (aa 1-186). In B16/ST tumor-bearing mice, this
vaccine, pcDNA3-MCC/ST, generated a significant num-
ber of ST antigenic peptide (aa 19-27)-specific CD8+ T
cells compared to mice vaccinated with empty vector.
Furthermore, pcDNA3-MCC/ST markedly enhanced sur-
vival in B16/ST tumor-bearing mice in tumor protection
Figure 2 Characterization of ST-specific CD8+ T cells using splenocytes stimulated with ST peptide aa 19-27. (A) Outline of the
vaccination schedule. C57BL/6 mice (5 per group) were immunized with pcDNA3-MCC/ST intradermally with DNA-coated particles using a
helium-driven gene gun 3 times at 4-day intervals. Pooled splenocytes from vaccinated mice were collected and cultured in vitro with
overlapping ST peptide overnight, and stained for intracellular IFN-γ and CD8+ cell surface marker. (B) Intracellular cytokine staining followed by
flow cytometry analysis to characterize ST-specific CD8+ T cell epitope using a single ST peptide (aa 19-27) from splenocytes harvested from mice
vaccinated with pcDNA3-MCC/ST or pcDNA3. (C) Bar graph of representative flow cytometry data showing the number of ST-specific CD8+ T
cells among 3 × 105 splenocytes. Note that peptide 19-27 activated the highest number of ST-specific CD8+ T cells.
Figure 3 In vivo tumor protection experiments. (A) An outline of the vaccination schedule using either pcDNA3-MCC/ST DNA vaccine or
empty vector control vaccine pcDNA3. C57BL/6 mice (5 per group) were immunized with either pcDNA3-MCC/ST or pcDNA3DNA vaccine
intradermally with DNA-coated particles using a helium-driven gene gun 3 times at 4-day intervals. Ten days after the last vaccination, vaccinated
mice were challenged subcutaneously in the right flank with B16/ST tumor (1×105 cells/mouse). (B) Survival plot depicting the percentage of
vaccinated mice surviving following vaccination with either pcDNA3-MCC/ST DNA vaccine or empty vector control pcDNA3. (C) Plot depicting
tumor volume over time. Tumors were measured with digital calipers and tumor volumes calculated.
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Figure 4 In vivo tumor treatment experiments. (A) Outline of the treatment regimen with either pcDNA3-ST DNA vaccine or empty vector
control pcDNA3. C57BL/6 mice (5 per group) were subcutaneously inoculated with B16/ST tumor (1×105 cells/mouse) in the right flank on D0.
Mice were monitored for evidence of tumor growth by visual inspection and palpation. Tumor growth was measured twice a week starting from
day 8 after tumor challenge. B16/ST-tumor bearing mice were treated with pcDNA3-MCC/ST or pcDNA3 intradermally with DNA-coated particles
using a helium-driven gene gun 3 times at 4-day intervals beginning three days after tumor inoculation. (B) Survival plot depicting the
percentage of vaccinated mice surviving following vaccination with either pcDNA3-MCC/ST DNA vaccine or control pcDNA3. (C) Plot depicting
tumor volume over time. Tumors were measured with digital calipers and tumor volumes calculated.
Figure 5 Characterization of the role of CD8+ T cells in tumor protection elicited by the pcDNA3-MCC/ST vaccine. Vaccinated mice were
boosted two times at the same dose and regimen at one week intervals. Beginning 1 day after last vaccination, vaccinated mice were
intraperitoneally injected with anti-CD8 monoclonal antibody other day. Antibody-depleted mice were then challenged with B16/ST tumor
(1×105 cells/mouse) subcutaneously in the right flank on day 22 after vaccination. Mice were monitored for evidence of tumor growth by inspection,
palpation and tumor size was measured once a week. (A) Survival analysis of B16/ST tumor-bearing mice treated with pcDNA3-MCC/ST DNA vaccine.
(B) Tumor size analysis of B16/ST tumor-bearing mice treated with pcDNA3-MCC/ST DNA vaccine.
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shown that CD8+ T cells play an essential role in the
therapeutic effect generated by the pcDNA-MCC/ST
vaccine. The formation of an effective vaccine against
MCPyV has the potential to advance the field of MCC
therapy and may contribute to the control of this severe
malignancy through immunotherapy.
The MCPyV ST-expressing tumor cell line established
in the current study may be useful the development
and testing of other therapeutic strategies for MCPyV-
associated malignancies, especially those targeting ST
antigen. Considering the oncogenic nature of ST anti-
gen, this tumor cell line could be quite valuable for the
characterization of molecular interventions targeting
ST antigen.
The current study shows that vaccination with pcDNA3-
MCC/ST DNA generates an appreciable ST-specific CD8+
T cell immune response systemically (Figure 2). Previously,
we have shown that the level of systemic antigen-specific
CD8+ T cells correlates with the level of antigen-specific
CD8+ T cells in the tumor loci [9]. Considering that
pcDNA3-MCC/ST DNA vaccine elicits potent therapeutic
antitumor effects (Figure 4), it is likely that these ST-specific
CD8+ T cells are present in tumor loci and contribute to
tumor control.
In order to advance the ST-targeting DNA vaccine toward
clinical translation, a few adjustments to the immunothera-
peutic strategy will have to be made. Firstly, a clinical grade
vector will be required to carry the ST DNA in place of
pcDNA3. An ideal candidate may be National Gene Vector
pNGVL4a, which has been previously used in clinical trials
of HPV-16 vaccines [10]. Furthermore, it will be important
to determine the most effective method of delivery for
the ST DNA vaccine. In the current study, we use both
intradermal vaccination by gene gun and electroporation to
enhance the efficacy of the DNA vaccine.
While this study provides evidence that a DNA vaccine
targeting MCPyV ST antigen can elicit an antitumor
immune response in B16 tumor-bearing mice, further
experiments will need to be undertaken to improve the
understanding of this methodology. It will be important to
compare the current treatment with strategies targeting
the other antigens of MCPyV, large T antigen and 57 kT
antigen. Additionally, therapies targeting multiple MCPyV
antigens should also be examined. For example, the ST
vaccine used here could be combined with our previously
developed large T DNA vaccine for a potentially more
potent MCC therapy [11].
In conclusion, this study presents the successful de-
velopment of a MCPyV ST-expressing tumor cell line
as well as an ST-targeting DNA vaccine capable of
eliciting antitumor effects. Additionally, further studies are
warranted to maximize the efficacy of the ST DNA vac-
cine as well as promote its advancement toward clinicalapplication. Both of these innovative technologies provide
opportunities to develop and test MCPyV-targeted therap-
ies for the control of Merkel cell carcinoma.
Materials and methods
Mice
C57BL/6 mice were purchased from National Cancer
Institute. All animals were maintained under specific
pathogen-free conditions, and all procedures were
performed according to approved protocols and in ac-
cordance with the recommendations for the proper use
and care of experimental animals.
Constructs
For the generation of the DNA vaccine (pcDNA3-MCC/ST)
encoding small T antigen (1-186 aa) of Merkel cell poly-
omavirus, small T antigen DNA (558 nt) was codon-
optimized and synthesized from GeneScript Corporation
(Piscataway, NJ) and cloned into NheI and NotI sites
of pcDNA3 (Invitrogen, Carlsbad, CA). For generation of
lentivirus encoding encoding truncated small T antigen,
the small T antigen DNA was cloned into NheI/NotI sites
of pCDH1-EF1-GFP vector (System Bioscience, Mountain
View, CA) to generate pCDH1-STop-EF1-GFP. The vector
contains two promoters, CMV promoter for small T
antigen and EF1 promoter for GFP expression.
Peptides
Previously, using 15 over-lapping amino acids spanning
aa 1-258 of the large T (LT) antigen of MCPyV, we identi-
fied the large T immunogenic epitope occurring at aa 19-27
(IAPNCYGNI) [11]. The small T antigen has a peptide
region that overlaps with that of the LT antigen, which
includes the epitope, MCPyV ST aa 19-27 (IAPNCYGNI),
as a region generating an ST-specific CD8+ T cell immune
response.
Cell lines
Small T and GFP-expressing B16F10 (B16/ST) were gen-
erated by transduction with a lentiviral vector containing
small T antigen and GFP. Lentiviral vector pCDH1-STop-
EF1-GFP, pCMVΔR8.91, and pMDG were transfected into
293T cell line using lipofectamine (Invitrogen) and the
virion-containing supernatant was collected 48 h after trans-
fection. The supernatant was then filtered through a 0.45
mm cellulose acetate syringe filter (Nalgene, Rochester, NY)
and used to infect B16F10 cells in the presence of 8 μg/ml
Polybrene Sigma-Aldrich, St Louis, MO). Transduced
cells were isolated using preparative flow cytometry with
GFP signal.
Western blot analysis
Whole cell protein lysates were obtained from both B16 and
sorted B16-MCC/ST cells and were extracted using M-PER
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Rockford, IL) containing complete protease inhibitor tablet
(Roche Diagnostic, Indianapolis, IN). Equal amounts of
proteins (30 μg) were loaded and separated by 4-15%
gradient ready SDS-PAGE gel. The gels were trans-
ferred to a polyvinylidene difluoride membrane (Bio-Rad,
Hercules, CA). Blots were blocked with phosphate-buffered
saline-Tween20 (PBST) containing 5% non-fat milk for 15
minutes at room temperature. Membranes were probed
with anti-β actin (Sigma, St. Louis, MO) at 1:5,000 dilution
or sera from mice vaccinated pcDNA3-MCC/ST at 1:100
dilution in PBST for 2.5 hours, washed several times with
PBST, and then incubated with rabbit anti-mouse IgG
conjugated to HRP (Invitrogen) at 1:5,000 dilution in PBST
containing 2.5% nonfat milk. Membranes were washed




RNA was extracted by TRIZOL (Invitrogen) from B16 and
B16/ST cell lines. PCR was performed using the Superscript
One-Step RT-PCR Kit (Invitrogen) using 1 μg of the
total RNA. Sequences of primers for small T antigen
and actin were as follows: small T-F (5′-CAAGGTTCT
GCAGGGGACCAGGATG -3′), small T-R (5′ GAACA
GGTGCAGGTGCAGCAGGCAG -3′), actin-F (5′-ACT
GGGACGACATGGAGAAG -3′), and actin-R (5′-GGGG
TGTTGAAGGTCTCAAA -3′). The reaction conditions
for small T antigen was 1 cycle (94°C, 30 sec), 35 cycles
(94°C, 30 sec; 55°C, 30 sec; 72°C, 30 sec), and 1 cycle
(72°C, 10 min). The reaction conditions for actin was
similar except that amplification was repeated for 25
cycles. The products were analyzed by electrophoresis
on a 1.5% agarose gel containing ethidium bromide.
DNA vaccination
In order to obtain sera for Western blot analysis, DNA
vaccine application was mediated by electroporation. The
Electroporation Delivery System (BTX, San Diego, CA)
was used according to the manufacturers protocol and as
described previously [12]. The vaccine was administered
three times at 1-week intervals and boosted at the
same dose using 40 μg of DNA per dose. C57BL/6 mice
(5 per group) were vaccinated with pcDNA3-MCC/ST.
For the remaining experiments, vaccine application
was performed using DNA-coated particles, which were
administered intradermally using a helium-driven gene
gun (Bio-Rad Laboratories, Hercules, California) using
methods previously described [13]. Briefly, C57BL/6 mice
(5 per group) were vaccinated with pcDNA3 or pcDNA3-
MCC/ST DNA-coated particles delivered to the shaved
abdominal region of each mouse using a helium-driven
gene gun with a discharge pressure of 400 psi. Micewere initially immunized at a dose of 2 μg of each
DNA vaccine and boosted with the same dose two
times at 4-day intervals.
In vivo tumor protection experiments
C57BL/6 mice (5 per group) were immunized with either
pcDNA3-MCC/ST or pcDNA3 empty vector DNA vac-
cine by gene gun as described above. One week after
the last vaccination, vaccinated mice were challenged
subcutaneously in the right flank with B16/ST tumor
cells (1×105 cells/mouse). Mice were monitored twice
per week for survival.
In vivo tumor treatment experiments
C57BL/6 mice (5 per group) were subcutaneously inocu-
lated with B16/ST tumor (1×105 cells/mouse) in the right
flank on D0. B16/ST-tumor bearing mice were treated with
pcDNA3-MCC/ST or pcDNA3 intradermally by a helium-
driven gene gun three times at 4-day intervals beginning
three days after tumor inoculation. Mice were monitored
twice per week for survival.
In vivo antibody depletion experiment
C57BL/6 mice (5 per group) were vaccinated by the gene
gun method with pcDNA3-MCC/ST vaccine on day 0.
Vaccinated mice were boosted two times at the same dose
and regimen at 1 week intervals. One day after the last vac-
cination, mice were intraperitoneally injected with anti-CD8
antibody every other day. Antibody-depleted mice were then
challenged with B16/ST tumor cells (1×105 cells/mouse)
subcutaneously in the right flank on day 22. Mice were
monitored for evidence of tumor growth by inspection and
palpation. Tumor size was measured twice a week.
Flow cytometry
Detection of cellular surface CD8a and intracellular IFN-γ
was performed using flow cytometry as described previ-
ously [14]. Briefly, the cells were incubated overnight with
1 μg/ml of GolgiPlug (BD Pharmingen) in the presence of
2 μg/ml of small T antigen overlapping peptides. After
washing with FACScan buffer, the cells were stained
with phycoerythrin-conjugated anti-mouse CD8a antibody.
The cells were then incubated with BD cytofix/cytoperm
solution (BD Pharmingen) followed by staining with
FITC-conjugated anti-mouse IFN-γ antibody. Flow cy-
tometry analysis was performed on a Becton-Dickinson
FACSCalibur with CELLQuest software (BD Biosciences,
Mountain View, CA).
Statistical analysis
Comparisons between individual data points were made
using a Student’s t-test. Kaplan-Meier survival curves were
applied for protection and tumor treatment experiments;
for differences between curves, p-values were calculated
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sidered significant.
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